Brussels, 31/01/2013 (Agence Europe) - On 31 January 2013, the European Commission sent a Statement of Objections to two pharmaceutical companies, Johnson & Johnson (J&J, United States) and Novartis (Switzerland) accusing them of delaying by 17 months the entry onto the Dutch market of a generic painkiller that is a cheaper alternative to J&J's Fentanyl, also accusing them of keeping the price of Fentanyl artificially high in the Dutch market through an agreement between the two companies'...